Who is the newest ACR, ARP or Rheumatology Research Foundation volunteer? Hopefully you. Volunteers, working side by side with staff, move the ACR forward. They are the voice through which our mission is put into action, ensuring we meet our members’ goals. Developing an effective pipeline of future volunteer leaders is essential to the future…
At first, there was an incomprehensibly loud explosion. And out of that explosion, about 4.5 billion years afterward, emerged the world’s first rheumatologist. Only a few notable things have happened between these two events, but the most important dynamic has been the continuous expansion of our universe. If the speculations of many cosmologists are correct,…
Sendaydiego et al. asked: Do some DMARDs pose a greater cancer risk than others for patients with RA? Here are insights from the study and its clinical implications.
FDA has granted Descartes-08, an mRNA chimeric antigen receptor T cell therapy, a rare pediatric disease designation for the treatment of juvenile dermatomyositis.
Reproductive health, biosimilars, IgG4-related disease and much more—five speakers give us a sneak peek into important topics being addressed at the ACR’s 2025 State-of-the-Art Clinical Symposium, April 4–6.
Building on her experiences in her practice and through the ACR, this rheumatology leader and educator is eager to advance the work of the COT.
Pulmonary hypertension and Raynaud’s phenomenon are just some of the symptoms patients with systemic sclerosis (SSc) may experience. Here are insights into the diagnosis and management of SSc.
In individuals without radiographic knee osteoarthritis (OA), Chang et al. investigated whether magnetic resonance imaging (MRI) defined knee OA at baseline was associated with incident radiographic and symptomatic disease during up to 11 years of follow-up. The researchers found the two current MRI definitions of knee OA may not adequately predict the development of radiographic and symptomatic disease.
Helping ACR/ARP members talk to lawmakers about rheumatology-related policy is a key part of the ACR’s advocacy efforts. A postcard-writing campaign to Congress highlights outreach efforts of a new member engagement working group.
As state legislatures begin to convene their sessions in 2025, several key issues related to rheumatology are expected to take center stage, including drug costs, utilization management, telehealth and copay accumulators.